Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
1733
mi
from 98109
Chicago, IL
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2485
mi
from 98109
Boston, MA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp. ACTG CRS (107)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2485
mi
from 98109
Boston, MA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital ACTG CRS (101)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2401
mi
from 98109
New York, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
NY Univ. HIV/AIDS CRS (401)
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2161
mi
from 98109
Rochester, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
AIDS Care CRS (1108)
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2161
mi
from 98109
Rochester, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Rochester ACTG CRS (1101)
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2337
mi
from 98109
Chapel Hill, NC
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Unc Aids Crs
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2341
mi
from 98109
Durham, NC
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Duke Univ. Med. Ctr. Adult CRS (1601)
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2020
mi
from 98109
Cleveland, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Metro Health CRS (2503)
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2132
mi
from 98109
Pittsburgh, PA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Pittsburgh CRS (1001)
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2486
mi
from 98109
Providence, RI
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital ACTG CRS (2951)
2486
mi
from 98109
Providence, RI
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
962
mi
from 98109
Los Angeles, CA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
704
mi
from 98109
Palo Alto, CA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Stanford CRS (501)
704
mi
from 98109
Palo Alto, CA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
680
mi
from 98109
San Francisco, CA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Ucsf Aids Crs (801)
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
1029
mi
from 98109
Aurora, CO
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2322
mi
from 98109
Washington,
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Georgetown University CRS (GU CRS) (1008)
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2732
mi
from 98109
Miami, FL
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS (901)
2732
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
1733
mi
from 98109
Chicago, IL
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2328
mi
from 98109
Baltimore, MD
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
IHV Baltimore Treatment CRS (4651)
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2485
mi
from 98109
Boston, MA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
1721
mi
from 98109
Saint Louis, MO
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Washington U CRS (2101)
1721
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2393
mi
from 98109
Newark, NJ
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)
2393
mi
from 98109
Newark, NJ
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2401
mi
from 98109
New York, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Cornell CRS (7804)
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2401
mi
from 98109
New York, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
HIV Prevention & Treatment CRS (30329)
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
1967
mi
from 98109
Cincinnati, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Univ. of Cincinnati CRS (2401)
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2020
mi
from 98109
Cleveland, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Case CRS (2501)
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2008
mi
from 98109
Columbus, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
The Ohio State Univ. AIDS CRS (2301)
2008
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 98109
Philadelphia, PA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2
mi
from 98109
Seattle, WA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS (1401)
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
3726
mi
from 98109
San Juan,
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Puerto Rico-AIDS CRS (5401)
3726
mi
from 98109
San Juan,
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
1730
mi
from 98109
Chicago, IL
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
UIC Project WISH CRS
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
681
mi
from 98109
San Francisco, CA
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Bridge HIV CRS
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
2484
mi
from 98109
Boston, MA
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
2484
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
2400
mi
from 98109
New York, NY
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Columbia P&S CRS
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
2402
mi
from 98109
New York, NY
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
New York Blood Center CRS
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
2161
mi
from 98109
Rochester, NY
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
University of Rochester Vaccines to Prevent HIV Infection CRS
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
2371
mi
from 98109
Philadelphia, PA
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Penn Prevention Crs
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
1971
mi
from 98109
Nashville, TN
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Vaccine (VV) CRS
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Feasibility of Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Status: Enrolling
Updated:  12/31/1969
2401
mi
from 98109
New York, NY
Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Feasibility of Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Status: Enrolling
Updated: 12/31/1969
City College of New York
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
2730
mi
from 98109
Miami, FL
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Pediatric Perinatal HIV Clinical Trials Unit CRS
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
1731
mi
from 98109
Chicago, IL
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital of Chicago (LCH) CRS
1731
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
6712
mi
from 98109
Belo Horizonte,
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
SOM Federal University Minas Gerais Brazil NICHD CRS
6712
mi
from 98109
Belo Horizonte,
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
2402
mi
from 98109
Bronx, NY
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Bronx-Lebanon Hospital Center NICHD CRS
2402
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
2405
mi
from 98109
Bronx, NY
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
2405
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases
Status: Enrolling
Updated:  12/31/1969
680
mi
from 98109
San Francisco, CA
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco, San Francisco General Hospital
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated:  12/31/1969
2110
mi
from 98109
Buffalo, NY
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
2110
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
2079
mi
from 98109
Birmingham, AL
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Alabama Therapeutics CRS (5801)
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
962
mi
from 98109
Los Angeles, CA
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
1029
mi
from 98109
Aurora, CO
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
1733
mi
from 98109
Chicago, IL
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials